Skip to main content
Premium Trial:

Request an Annual Quote

Solvias Acquires Dutch Genomics Firm Cergentis

NEW YORK — Swiss contract research and manufacturing firm Solvias said on Tuesday that it has acquired Cergentis, a provider of genomic analysis and genetic quality control services.

Financial and other terms of the transaction were not disclosed.

Solvias said that the acquisition expands its offerings for biologics and cell and gene therapy testing, as well as its customer service network.

"Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies," Solvias CEO Archie Cullen said in a statement. "We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry."

Cergentis has been providing services based on its genomic analysis platform to biopharmaceutical firms and research institutions. About a year ago, the Utrecht, Netherlands-based company published data showcasing the ability of its targeted locus amplification (TLA) gene sequencing technology to characterize translocations in lymphoma.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.